Ashktorab Hassan, Pizuorno Antonio, Chirumamilla Lakshmi Gayathri, Adeleye Folake, Dalivand Maryam Mehdipour, Sherif Zaki A, Oskrochi Gholamreza, Challa Suryanarayana Reddy, Jones-Wonni Boubini, Rankine Sheldon, Ekwunazu Chiamaka, Banson Abigail, Kim Rachel, Gilliard Chandler, Ekpe Elizabeth, Shayegh Nader, Nyaunu Constance, Martins Chidi, Slack Ashley, Okwesili Princess, Abebe Malachi, Batta Yashvardhan, Ly Do, Valarie Ogwo, Smith Tori, Watson Kyra, Kolawole Oluwapelumi, Tahmazian Sarine, Atoba Sofiat, Khushbakht Myra, Riley Gregory, Gavin Warren, Kara Areeba, Hache-Marliere Manuel, Palaiodimos Leonidas, Mani Vishnu R, Kalabin Aleksandr, Gayam Vijay Reddy, Garlapati Pavani Reddy, Miller Joseph, Jackson Fatimah, Carethers John M, Rustgi Vinod, Brim Hassan
Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
Department of Pathology and Cancer Center, Department of Biochemistry & Molecular Biology, Howard University College of Medicine, Washington DC, USA.
Arch Intern Med Res. 2024;7(1):27-41. doi: 10.26502/aimr.0163. Epub 2024 Feb 16.
Identifying clinical characteristics and outcomes of different ethnicities in the US may inform treatment for hospitalized COVID-19 patients. Aim of this study is to identify predictors of mortality among US races/ethnicities.
We retrospectively analyzed de-identified data from 9,873 COVID-19 patients who were hospitalized at 15 US hospital centers in 11 states (March 2020-November 2020). Main Outcomes and Measures: The primary outcome was to identify predictors of mortality in hospitalized COVID-19 patients.
Among the 9,873 patients, there were 64.1% African Americans (AA), 19.8% Caucasians, 10.4% Hispanics, and 5.7% Asians, with 50.7% female. Males showed higher in-hospital mortality (20.9% vs. 15.3%, p=0.001). Non- survivors were significantly older (67 vs. 61 years) than survivors. Patients in New York had the highest in-hospital mortality (OR=3.54 (3.03 - 4.14)). AA patients possessed higher prevalence of comorbidities, had longer hospital stay, higher ICU admission rates, increased requirement for mechanical ventilation and higher in-hospital mortality compared to other races/ethnicities. Gastrointestinal symptoms (GI), particularly diarrhea, were more common among minority patients. Among GI symptoms and laboratory findings, abdominal pain (5.3%, p=0.03), elevated AST (n=2653, 50.2%, p=<0.001, OR=2.18), bilirubin (n=577, 12.9%, p=0.01) and low albumin levels (n=361, 19.1%, p=0.03) were associated with mortality. Multivariate analysis (adjusted for age, sex, race, geographic location) indicates that patients with asthma, COPD, cardiac disease, hypertension, diabetes mellitus, immunocompromised status, shortness of breath and cough possess higher odds of in-hospital mortality. Among laboratory parameters, patients with lymphocytopenia (OR2=2.50), lymphocytosis (OR2=1.41), and elevations of serum CRP (OR2=4.19), CPK (OR2=1.43), LDH (OR2=2.10), troponin (OR2=2.91), ferritin (OR2=1.88), AST (OR2=2.18), D-dimer (OR2=2.75) are more prone to death. Patients on glucocorticoids (OR2=1.49) and mechanical ventilation (OR2=9.78) have higher in-hospital mortality.
These findings suggest that older age, male sex, AA race, and hospitalization in New York were associated with higher in-hospital mortality rates from COVID-19 in early pandemic stages. Other predictors of mortality included the presence of comorbidities, shortness of breath, cough elevated serum inflammatory markers, altered lymphocyte count, elevated AST, and low serum albumin. AA patients comprised a disproportionate share of COVID-19 death in the US during 2020 relative to other races/ethnicities.
识别美国不同种族的临床特征和预后情况,可为住院的新冠病毒疾病(COVID - 19)患者的治疗提供参考。本研究的目的是确定美国不同种族/民族中死亡的预测因素。
设计、背景与参与者:我们回顾性分析了来自美国11个州15家医院中心9873例COVID - 19住院患者的去标识化数据(2020年3月至2020年11月)。主要结局与测量指标:主要结局是确定COVID - 19住院患者死亡的预测因素。
在9873例患者中,非裔美国人(AA)占64.1%,白种人占19.8%,西班牙裔占10.4%,亚裔占5.7%,女性占50.7%。男性的院内死亡率更高(20.9%对15.3%,p = 0.001)。非幸存者比幸存者年龄显著更大(67岁对61岁)。纽约的患者院内死亡率最高(OR = 3.54(3.03 - 4.14))。与其他种族/民族相比,AA患者合并症患病率更高,住院时间更长,重症监护病房(ICU)入住率更高,机械通气需求增加,院内死亡率更高。胃肠道症状(GI),尤其是腹泻,在少数族裔患者中更常见。在胃肠道症状和实验室检查结果中,腹痛(5.3%,p = 0.03)、谷草转氨酶升高(n = 2653,50.2%,p < 0.001,OR = 2.18)、胆红素(n = 577,12.9%,p = 0.01)和白蛋白水平低(n = 361,19.1%,p = 0.03)与死亡率相关。多因素分析(校正年龄、性别、种族、地理位置)表明,患有哮喘、慢性阻塞性肺疾病(COPD)、心脏病、高血压、糖尿病、免疫功能低下、呼吸急促和咳嗽的患者院内死亡几率更高。在实验室参数方面,淋巴细胞减少(OR2 = 2.50)、淋巴细胞增多(OR2 = 1.41)以及血清C反应蛋白(CRP)升高(OR2 = 4.19)、肌酸磷酸激酶(CPK)升高(OR = 1.43)、乳酸脱氢酶(LDH)升高(OR2 = 2.10)、肌钙蛋白升高(OR2 = 2.91)、铁蛋白升高(OR2 = 1.88)、谷草转氨酶升高(OR2 = 2.18)、D - 二聚体升高(OR2 = 2.75)的患者更容易死亡。接受糖皮质激素治疗(OR2 = 1.49)和机械通气(OR2 = 9.78)的患者院内死亡率更高。
这些发现表明,在疫情早期阶段,年龄较大、男性、AA种族以及在纽约住院与COVID - 19更高的院内死亡率相关。其他死亡预测因素包括合并症的存在、呼吸急促、咳嗽、血清炎症标志物升高、淋巴细胞计数改变、谷草转氨酶升高和血清白蛋白水平低。相对于其他种族/民族,2020年美国AA患者在COVID - 19死亡中所占比例过高。